

FOI 3764

29th May 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1a – How many patients were treated with the following drugs for the following diseases from the start of January 2026 to the end of March 2026?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Response:

Current patients as of 14/05/26

Drug Name	Plaque psoriasis	Psoriatic arthritis
Adalimumab	262	252
Apremilast	0	
Bimekizumab	19	
Brodalumab	5	
Certolizumab Pegol	7	
Deucravacitinib	0	
Etanercept	<5	
Etrasimod		
Filgotinib		
Golimumab		
Guselkumab	70	14
Infliximab (Biosimilars)	<5	9
Infliximab (Remicade)	0	0
Ixekizumab	118	
Mirikizumab		
Ozanimod		
Risankizumab	142	<5
Secukinumab	29	
Tildrakizumab	5	

Tofacitinib		
Upadacitinib		9
Ustekinumab	26	<5
Vedolizumab		

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net